160 related articles for article (PubMed ID: 23811808)
1. Acute reduction of lipolysis reduces adiponectin and IL-18: evidence from an intervention study with acipimox and insulin.
Lindegaard B; Ditlevsen S; Plomgaard P; Mittendorfer B; Pedersen BK
Diabetologia; 2013 Sep; 56(9):2034-43. PubMed ID: 23811808
[TBL] [Abstract][Full Text] [Related]
2. Plasma adiponectin is modestly decreased during 24-hour insulin infusion but not after inhibition of lipolysis by Acipimox.
Dullaart RP; Riemens SC; Meinardi JR; Wolffenbuttel BH; Sluiter WJ
Scand J Clin Lab Invest; 2005; 65(6):523-31. PubMed ID: 16179286
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
Lindegaard B; Frøsig C; Petersen AM; Plomgaard P; Ditlevsen S; Mittendorfer B; Van Hall G; Wojtaszewski JF; Pedersen BK
Diabetes; 2007 Aug; 56(8):2070-7. PubMed ID: 17601993
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution.
Hadigan C; Rabe J; Meininger G; Aliabadi N; Breu J; Grinspoon S
Am J Clin Nutr; 2003 Feb; 77(2):490-4. PubMed ID: 12540412
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals.
Hjelholt AJ; Charidemou E; Griffin JL; Pedersen SB; Gudiksen A; Pilegaard H; Jessen N; Møller N; Jørgensen JOL
Diabetologia; 2020 Dec; 63(12):2641-2653. PubMed ID: 32945898
[TBL] [Abstract][Full Text] [Related]
6. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
8. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
9. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
10. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
12. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
Hadigan C; Liebau J; Torriani M; Andersen R; Grinspoon S
J Clin Endocrinol Metab; 2006 Nov; 91(11):4438-44. PubMed ID: 16940448
[TBL] [Abstract][Full Text] [Related]
13. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Nielsen S; Møller N; Christiansen JS; Jørgensen JO
Diabetes; 2001 Oct; 50(10):2301-8. PubMed ID: 11574412
[TBL] [Abstract][Full Text] [Related]
16. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes.
Christie AW; McCormick DK; Emmison N; Kraemer FB; Alberti KG; Yeaman SJ
Diabetologia; 1996 Jan; 39(1):45-53. PubMed ID: 8720602
[TBL] [Abstract][Full Text] [Related]
18. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
Vaag AA; Beck-Nielsen H
Acta Endocrinol (Copenh); 1992 Oct; 127(4):344-50. PubMed ID: 1449046
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of lipolysis in Type 2 diabetes normalizes glucose disposal without change in muscle glycogen synthesis rates.
Lim EL; Hollingsworth KG; Smith FE; Thelwall PE; Taylor R
Clin Sci (Lond); 2011 Aug; 121(4):169-77. PubMed ID: 21388348
[TBL] [Abstract][Full Text] [Related]
20. The effect of an antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Taskinen MR
Acta Diabetol; 1994 Apr; 31(1):6-13. PubMed ID: 8043900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
